Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Clinical pharmacokinetics and pharmacodynamics of gemifloxacin in healthy Chinese volunteers following multiple oral administration

Clinical pharmacokinetics of gemifloxacin following single oral dose administration in healthy Chinese male subjects

Study on Pharmacokinetics of Multi-Dose of Oral Gatifloxacin Methanesulfonate Tablets in Healthy Volunteers

A study on multi-dose pharmacokinetics of gatifloxacin mesylate in healthy volunteers

Pharmacokinetics of gatifloxacin mesylate tablet in healthy volunteers after a single oral administration

Pharmacokinetics of Gatifloxacin Tablet in Healthy Volunteers

Pharmacokinetics Study of Pazufloxacin Mesilate after Multiple Doses in Chinese Healthy Volunteers

Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization

Pharmacokinetics of Pazufloxacin Mesilate in Chinese Healthy Volunteers

Pharmacokinetics And Pharmacodynamics Of Levofloxacin Injection In Healthy Chinese Volunteers And Dosing Regimen Optimization

Pharmacokinetics study of pazufloxacin mesylate in single dose in Chinese healthy volunteers

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

Pharmacokinetic Study of Single and Multiple Oral Dose Administration of Antofloxacin Hydrochloride in Healthy Male Volunteers.

A Randomized, Controlled, Multicenter Clinical Trial To Evaluate The Efficacy And Safety Of Oral Sitafloxacin Versus Moxifloxacin In Adult Patients With Community-Acquired Pneumonia

Population Pharmacokinetics of Oral Levofloxacin 500mg Once-Daily Dosage in Community-Acquired Lower Respiratory Tract Infections: Results of a Prospective Multicenter Study in China

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetics of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, after Single-Dose Intravenous Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics of pazufloxacin single dose intravenous in healthy volunteers

Pharmacokinetics of Multiple - Dose Pazufloxacin Mesilate Sodium Chloride Injection in Chinese Healthy Volunteers